Danaher Co. (NYSE:DHR) Shares Sold by Arthur M. Cohen & Associates LLC

Arthur M. Cohen & Associates LLC trimmed its holdings in Danaher Co. (NYSE:DHR) by 3.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 206,211 shares of the conglomerate’s stock after selling 6,428 shares during the quarter. Danaher comprises about 8.1% of Arthur M. Cohen & Associates LLC’s portfolio, making the stock its 2nd biggest position. Arthur M. Cohen & Associates LLC’s holdings in Danaher were worth $42,273,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in DHR. Spinnaker Trust increased its stake in shares of Danaher by 1.2% in the fourth quarter. Spinnaker Trust now owns 4,304 shares of the conglomerate’s stock worth $988,000 after purchasing an additional 50 shares in the last quarter. Fortis Capital Advisors LLC increased its stake in Danaher by 1.3% in the 4th quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate’s stock worth $914,000 after buying an additional 50 shares in the last quarter. Fayez Sarofim & Co raised its holdings in Danaher by 0.6% during the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate’s stock valued at $1,902,000 after acquiring an additional 50 shares during the period. Coastal Bridge Advisors LLC lifted its position in shares of Danaher by 4.8% in the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate’s stock valued at $252,000 after acquiring an additional 50 shares in the last quarter. Finally, Perennial Investment Advisors LLC boosted its stake in shares of Danaher by 2.2% in the fourth quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate’s stock worth $538,000 after acquiring an additional 51 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE DHR opened at $193.21 on Thursday. The company has a market cap of $138.27 billion, a P/E ratio of 36.59, a P/E/G ratio of 2.66 and a beta of 0.80. The business’s 50 day moving average price is $191.68 and its 200-day moving average price is $212.83. Danaher Co. has a fifty-two week low of $171.00 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.26. Danaher had a net margin of 16.33% and a return on equity of 10.82%. The business had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.58 billion. Sell-side analysts predict that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.66%. Danaher’s dividend payout ratio is 24.85%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Guggenheim reissued a “buy” rating and issued a $250.00 price target on shares of Danaher in a report on Wednesday, April 23rd. JPMorgan Chase & Co. lowered their target price on shares of Danaher from $280.00 to $260.00 and set an “overweight” rating on the stock in a report on Tuesday, April 22nd. UBS Group cut their target price on shares of Danaher from $275.00 to $240.00 and set a “buy” rating for the company in a research note on Wednesday, April 23rd. Barclays lifted their price target on shares of Danaher from $205.00 to $215.00 and gave the company an “overweight” rating in a report on Tuesday, April 22nd. Finally, Stifel Nicolaus upgraded Danaher from a “hold” rating to a “buy” rating and set a $260.00 price objective for the company in a research report on Friday, March 14th. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $263.24.

Insider Transactions at Danaher

In other news, EVP Christopher Paul Riley sold 15,805 shares of the company’s stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the transaction, the executive vice president now directly owns 15,179 shares in the company, valued at approximately $3,005,442. This represents a 51.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of the company’s stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman now owns 3,105,808 shares in the company, valued at $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.10% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.